CD44 and ovarian cancer: A6 peptide, a short amino acid sequence targeting the HA-binding domain of CD44, performed well in increasing the time to progression of patients with ovarian cancer: half of the patients with asymptomatic biochemical recurrence experienced periods of stable disease for at least 4 cycles of administered A6 peptide therapy (Ghamande et al., 2008).